Hansoh Pharmaceutical Group Company Limited (3692)

Name: Hansoh Pharmaceutical Group Company Limited (3692) — histórico de demonstrações financeiras
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

Histórico de receita, lucros e fluxo de caixa das demonstrações financeiras oficiais.

Healthcare · Wall Street (EUA) · Última atualização: 2026-09-30

Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People's Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases.

Números-chave

Capitalização de mercado: HK$214 billion
Receita (exercício encerrado em 2025-12-31): CNY 15.0B
Lucro líquido: CNY 5.6B
Margem bruta: 90.0%
Margem líquida: 37.0%

Ver gráficos interativos e demonstrações completas → Modelo de avaliação (DCF) →

Demonstração de resultados anual

Demonstração de resultados	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Receita total	CNY 15.0B	CNY 12.3B	CNY 10.1B	CNY 9.4B
Lucro bruto	CNY 13.5B	CNY 11.2B	CNY 9.1B	CNY 8.5B
Resultado Operacional (EBIT)	CNY 5.5B	CNY 4.0B	CNY 2.8B	CNY 2.8B
Resultado líquido	CNY 5.6B	CNY 4.4B	CNY 3.3B	CNY 2.6B

Fonte: relatórios públicos da empresa (SEC). Verifique no SEC EDGAR antes de confiar em qualquer número.

Balanços, fluxos de caixa, dados trimestrais e indicadores completos no visualizador interativo de 3692. /companies/us/3692

Empresas semelhantes

As informações deste site são apenas educacionais e informativas; não constituem recomendação de investimento. Não publicamos preços-alvo nem recomendações.

English version →Todas as ações

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.